Shandong Xinhua Pharmaceutical Wins NMPA Approval for Glucosamine Sulfate Capsules

An update from Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) is now available.

Shandong Xinhua Pharmaceutical Company Limited has received a Drug Registration Certificate from China’s National Medical Products Administration for its Glucosamine Sulfate Capsules, an over-the-counter, Category A non-prescription chemical drug. The approval covers specified dosages and requires the company to finalize quality standards, labeling, and production processes in line with pharmaceutical production quality management requirements before commercial manufacture and sale.

The product application was filed with the Center for Drug Evaluation in August 2024 and approved in February 2026, marking a successful addition to Xinhua Pharmaceutical’s OTC portfolio. This regulatory milestone is expected to support the company’s domestic market positioning in musculoskeletal and joint health therapies, potentially broadening revenue streams once production and sales commence under the approved standards.

The most recent analyst rating on (HK:0719) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on Shandong Xinhua Pharmaceutical Company Limited Class H stock, see the HK:0719 Stock Forecast page.

More about Shandong Xinhua Pharmaceutical Company Limited Class H

Shandong Xinhua Pharmaceutical Company Limited is a PRC-based pharmaceutical manufacturer listed in Hong Kong and on the mainland, engaged in the development and production of chemical drugs. The company participates in both prescription and over-the-counter markets, supplying a range of formulated products and focusing on expanding its domestic drug portfolio.

Average Trading Volume: 1,987,934

Technical Sentiment Signal: Buy

Current Market Cap: HK$10.37B

For an in-depth examination of 0719 stock, go to TipRanks’ Overview page.